Axsome Therapeutics Inc


Market Cap$3.81B

Compare Axsome Therapeutics

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Axsome Therapeutics IncAxsome Therapeutics Inc-18.90%-75%20.60.7
marketMarket Avg49.61.28%30%6.11.1
HealthcareHealthcare Avg32.71.25%19%7.40.9

Current Fair Value

1.2% downside

Overvalued by 1.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$3.81 Billion
Enterprise Value$3.58 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$-4.54
Outstanding Shares47,319,547
Avg 30 Day Volume719,510


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-18.87
Price to Sales20.58
Price to Book Ratio16.46
Enterprise Value to Revenue16.01
Enterprise Value to EBIT-19.49
Enterprise Value to Net Income-18
Total Debt to Enterprise0.05
Debt to Equity0.69

Revenue Sources

No data

ESG Score

No data

About Axsome Therapeutics Inc

CEO: Herriot Tabuteau

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...